

Global Live Attenuated Herpes Zoster Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G8043DEE67BCEN.html>

Date: April 2023

Pages: 73

Price: US\$ 3,480.00 (Single User License)

ID: G8043DEE67BCEN

Abstracts

According to our (Global Info Research) latest study, the global Live Attenuated Herpes Zoster Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Live Attenuated Herpes Zoster Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Suitable Age and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Live Attenuated Herpes Zoster Vaccine market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Live Attenuated Herpes Zoster Vaccine market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Live Attenuated Herpes Zoster Vaccine market size and forecasts, by Suitable

Age and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Live Attenuated Herpes Zoster Vaccine market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Live Attenuated Herpes Zoster Vaccine

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Live Attenuated Herpes Zoster Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck & Co., SK Bioscience, GlaxoSmithKline (GSK) and Beike Bio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Live Attenuated Herpes Zoster Vaccine market is split by Suitable Age and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Suitable Age, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Suitable Age

40-50 Years Old

50-60 Years Old

60-70 Years Old

>70 Years Old

Market segment by Application

Hospital

Clinic

Epidemic Prevention Center

Others

Major players covered

Merck & Co.

SK Bioscience

GlaxoSmithKline (GSK)

Beike Bio

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of

Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Live Attenuated Herpes Zoster Vaccine product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Live Attenuated Herpes Zoster Vaccine, with price, sales, revenue and global market share of Live Attenuated Herpes Zoster Vaccine from 2018 to 2023.

Chapter 3, the Live Attenuated Herpes Zoster Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Live Attenuated Herpes Zoster Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Suitable Age and application, with sales market share and growth rate by suitable age, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022. and Live Attenuated Herpes Zoster Vaccine market forecast, by regions, suitable age and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Live Attenuated Herpes Zoster Vaccine.

Chapter 14 and 15, to describe Live Attenuated Herpes Zoster Vaccine sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Live Attenuated Herpes Zoster Vaccine
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Suitable Age
 - 1.3.1 Overview: Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Suitable Age: 2018 Versus 2022 Versus 2029
 - 1.3.2 40-50 Years Old
 - 1.3.3 50-60 Years Old
 - 1.3.4 60-70 Years Old
 - 1.3.5 >70 Years Old
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Hospital
 - 1.4.3 Clinic
 - 1.4.4 Epidemic Prevention Center
 - 1.4.5 Others
- 1.5 Global Live Attenuated Herpes Zoster Vaccine Market Size & Forecast
 - 1.5.1 Global Live Attenuated Herpes Zoster Vaccine Consumption Value (2018 & 2022 & 2029)
 - 1.5.2 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity (2018-2029)
 - 1.5.3 Global Live Attenuated Herpes Zoster Vaccine Average Price (2018-2029)

2 MANUFACTURERS PROFILES

- 2.1 Merck & Co.
 - 2.1.1 Merck & Co. Details
 - 2.1.2 Merck & Co. Major Business
 - 2.1.3 Merck & Co. Live Attenuated Herpes Zoster Vaccine Product and Services
 - 2.1.4 Merck & Co. Live Attenuated Herpes Zoster Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.1.5 Merck & Co. Recent Developments/Updates
- 2.2 SK Bioscience
 - 2.2.1 SK Bioscience Details
 - 2.2.2 SK Bioscience Major Business
 - 2.2.3 SK Bioscience Live Attenuated Herpes Zoster Vaccine Product and Services

2.2.4 SK Bioscience Live Attenuated Herpes Zoster Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 SK Bioscience Recent Developments/Updates

2.3 GlaxoSmithKline (GSK)

2.3.1 GlaxoSmithKline (GSK) Details

2.3.2 GlaxoSmithKline (GSK) Major Business

2.3.3 GlaxoSmithKline (GSK) Live Attenuated Herpes Zoster Vaccine Product and Services

2.3.4 GlaxoSmithKline (GSK) Live Attenuated Herpes Zoster Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 GlaxoSmithKline (GSK) Recent Developments/Updates

2.4 Beike Bio

2.4.1 Beike Bio Details

2.4.2 Beike Bio Major Business

2.4.3 Beike Bio Live Attenuated Herpes Zoster Vaccine Product and Services

2.4.4 Beike Bio Live Attenuated Herpes Zoster Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Beike Bio Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: LIVE ATTENUATED HERPES ZOSTER VACCINE BY MANUFACTURER

3.1 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Manufacturer (2018-2023)

3.2 Global Live Attenuated Herpes Zoster Vaccine Revenue by Manufacturer (2018-2023)

3.3 Global Live Attenuated Herpes Zoster Vaccine Average Price by Manufacturer (2018-2023)

3.4 Market Share Analysis (2022)

3.4.1 Producer Shipments of Live Attenuated Herpes Zoster Vaccine by Manufacturer Revenue (\$MM) and Market Share (%): 2022

3.4.2 Top 3 Live Attenuated Herpes Zoster Vaccine Manufacturer Market Share in 2022

3.4.2 Top 6 Live Attenuated Herpes Zoster Vaccine Manufacturer Market Share in 2022

3.5 Live Attenuated Herpes Zoster Vaccine Market: Overall Company Footprint Analysis

3.5.1 Live Attenuated Herpes Zoster Vaccine Market: Region Footprint

3.5.2 Live Attenuated Herpes Zoster Vaccine Market: Company Product Type Footprint

- 3.5.3 Live Attenuated Herpes Zoster Vaccine Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global Live Attenuated Herpes Zoster Vaccine Market Size by Region
 - 4.1.1 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2018-2029)
 - 4.1.2 Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2018-2029)
 - 4.1.3 Global Live Attenuated Herpes Zoster Vaccine Average Price by Region (2018-2029)
- 4.2 North America Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029)
- 4.3 Europe Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029)
- 4.4 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029)
- 4.5 South America Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029)
- 4.6 Middle East and Africa Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029)

5 MARKET SEGMENT BY SUITABLE AGE

- 5.1 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2029)
- 5.2 Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Suitable Age (2018-2029)
- 5.3 Global Live Attenuated Herpes Zoster Vaccine Average Price by Suitable Age (2018-2029)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2029)
- 6.2 Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Application (2018-2029)

6.3 Global Live Attenuated Herpes Zoster Vaccine Average Price by Application (2018-2029)

7 NORTH AMERICA

7.1 North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2029)

7.2 North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2029)

7.3 North America Live Attenuated Herpes Zoster Vaccine Market Size by Country

7.3.1 North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2018-2029)

7.3.2 North America Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2018-2029)

7.3.3 United States Market Size and Forecast (2018-2029)

7.3.4 Canada Market Size and Forecast (2018-2029)

7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

8.1 Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2029)

8.2 Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2029)

8.3 Europe Live Attenuated Herpes Zoster Vaccine Market Size by Country

8.3.1 Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2018-2029)

8.3.2 Europe Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2018-2029)

8.3.3 Germany Market Size and Forecast (2018-2029)

8.3.4 France Market Size and Forecast (2018-2029)

8.3.5 United Kingdom Market Size and Forecast (2018-2029)

8.3.6 Russia Market Size and Forecast (2018-2029)

8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

9.1 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2029)

9.2 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2029)

9.3 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Market Size by Region

9.3.1 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2018-2029)

9.3.2 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2018-2029)

9.3.3 China Market Size and Forecast (2018-2029)

9.3.4 Japan Market Size and Forecast (2018-2029)

9.3.5 Korea Market Size and Forecast (2018-2029)

9.3.6 India Market Size and Forecast (2018-2029)

9.3.7 Southeast Asia Market Size and Forecast (2018-2029)

9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

10.1 South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2029)

10.2 South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2029)

10.3 South America Live Attenuated Herpes Zoster Vaccine Market Size by Country

10.3.1 South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2018-2029)

10.3.2 South America Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2018-2029)

10.3.3 Brazil Market Size and Forecast (2018-2029)

10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2029)

11.2 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2029)

11.3 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Market Size by Country

11.3.1 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2018-2029)

11.3.2 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Consumption

Value by Country (2018-2029)

11.3.3 Turkey Market Size and Forecast (2018-2029)

11.3.4 Egypt Market Size and Forecast (2018-2029)

11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)

11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

12.1 Live Attenuated Herpes Zoster Vaccine Market Drivers

12.2 Live Attenuated Herpes Zoster Vaccine Market Restraints

12.3 Live Attenuated Herpes Zoster Vaccine Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

12.5 Influence of COVID-19 and Russia-Ukraine War

12.5.1 Influence of COVID-19

12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Live Attenuated Herpes Zoster Vaccine and Key Manufacturers

13.2 Manufacturing Costs Percentage of Live Attenuated Herpes Zoster Vaccine

13.3 Live Attenuated Herpes Zoster Vaccine Production Process

13.4 Live Attenuated Herpes Zoster Vaccine Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Live Attenuated Herpes Zoster Vaccine Typical Distributors

14.3 Live Attenuated Herpes Zoster Vaccine Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Suitable Age, (USD Million), 2018 & 2022 & 2029

Table 2. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Merck & Co. Basic Information, Manufacturing Base and Competitors

Table 4. Merck & Co. Major Business

Table 5. Merck & Co. Live Attenuated Herpes Zoster Vaccine Product and Services

Table 6. Merck & Co. Live Attenuated Herpes Zoster Vaccine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 7. Merck & Co. Recent Developments/Updates

Table 8. SK Bioscience Basic Information, Manufacturing Base and Competitors

Table 9. SK Bioscience Major Business

Table 10. SK Bioscience Live Attenuated Herpes Zoster Vaccine Product and Services

Table 11. SK Bioscience Live Attenuated Herpes Zoster Vaccine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 12. SK Bioscience Recent Developments/Updates

Table 13. GlaxoSmithKline (GSK) Basic Information, Manufacturing Base and Competitors

Table 14. GlaxoSmithKline (GSK) Major Business

Table 15. GlaxoSmithKline (GSK) Live Attenuated Herpes Zoster Vaccine Product and Services

Table 16. GlaxoSmithKline (GSK) Live Attenuated Herpes Zoster Vaccine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 17. GlaxoSmithKline (GSK) Recent Developments/Updates

Table 18. Beike Bio Basic Information, Manufacturing Base and Competitors

Table 19. Beike Bio Major Business

Table 20. Beike Bio Live Attenuated Herpes Zoster Vaccine Product and Services

Table 21. Beike Bio Live Attenuated Herpes Zoster Vaccine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 22. Beike Bio Recent Developments/Updates

Table 23. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by

Manufacturer (2018-2023) & (K Units)

Table 24. Global Live Attenuated Herpes Zoster Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)

Table 25. Global Live Attenuated Herpes Zoster Vaccine Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 26. Market Position of Manufacturers in Live Attenuated Herpes Zoster Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022

Table 27. Head Office and Live Attenuated Herpes Zoster Vaccine Production Site of Key Manufacturer

Table 28. Live Attenuated Herpes Zoster Vaccine Market: Company Product Type Footprint

Table 29. Live Attenuated Herpes Zoster Vaccine Market: Company Product Application Footprint

Table 30. Live Attenuated Herpes Zoster Vaccine New Market Entrants and Barriers to Market Entry

Table 31. Live Attenuated Herpes Zoster Vaccine Mergers, Acquisition, Agreements, and Collaborations

Table 32. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2018-2023) & (K Units)

Table 33. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2024-2029) & (K Units)

Table 34. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2018-2023) & (USD Million)

Table 35. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2024-2029) & (USD Million)

Table 36. Global Live Attenuated Herpes Zoster Vaccine Average Price by Region (2018-2023) & (US\$/Unit)

Table 37. Global Live Attenuated Herpes Zoster Vaccine Average Price by Region (2024-2029) & (US\$/Unit)

Table 38. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2023) & (K Units)

Table 39. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2024-2029) & (K Units)

Table 40. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Suitable Age (2018-2023) & (USD Million)

Table 41. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Suitable Age (2024-2029) & (USD Million)

Table 42. Global Live Attenuated Herpes Zoster Vaccine Average Price by Suitable Age (2018-2023) & (US\$/Unit)

Table 43. Global Live Attenuated Herpes Zoster Vaccine Average Price by Suitable Age (2024-2029) & (US\$/Unit)

Table 44. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2023) & (K Units)

Table 45. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2024-2029) & (K Units)

Table 46. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Application (2018-2023) & (USD Million)

Table 47. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Application (2024-2029) & (USD Million)

Table 48. Global Live Attenuated Herpes Zoster Vaccine Average Price by Application (2018-2023) & (US\$/Unit)

Table 49. Global Live Attenuated Herpes Zoster Vaccine Average Price by Application (2024-2029) & (US\$/Unit)

Table 50. North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2023) & (K Units)

Table 51. North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2024-2029) & (K Units)

Table 52. North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2023) & (K Units)

Table 53. North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2024-2029) & (K Units)

Table 54. North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2018-2023) & (K Units)

Table 55. North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2024-2029) & (K Units)

Table 56. North America Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2018-2023) & (USD Million)

Table 57. North America Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2024-2029) & (USD Million)

Table 58. Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2023) & (K Units)

Table 59. Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2024-2029) & (K Units)

Table 60. Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2023) & (K Units)

Table 61. Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2024-2029) & (K Units)

Table 62. Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country

(2018-2023) & (K Units)

Table 63. Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2024-2029) & (K Units)

Table 64. Europe Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2018-2023) & (USD Million)

Table 65. Europe Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2024-2029) & (USD Million)

Table 66. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2023) & (K Units)

Table 67. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2024-2029) & (K Units)

Table 68. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2023) & (K Units)

Table 69. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2024-2029) & (K Units)

Table 70. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2018-2023) & (K Units)

Table 71. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2024-2029) & (K Units)

Table 72. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2018-2023) & (USD Million)

Table 73. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2024-2029) & (USD Million)

Table 74. South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2023) & (K Units)

Table 75. South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2024-2029) & (K Units)

Table 76. South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2023) & (K Units)

Table 77. South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2024-2029) & (K Units)

Table 78. South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2018-2023) & (K Units)

Table 79. South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2024-2029) & (K Units)

Table 80. South America Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2018-2023) & (USD Million)

Table 81. South America Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2024-2029) & (USD Million)

Table 82. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2018-2023) & (K Units)

Table 83. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Suitable Age (2024-2029) & (K Units)

Table 84. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2018-2023) & (K Units)

Table 85. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2024-2029) & (K Units)

Table 86. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2018-2023) & (K Units)

Table 87. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2024-2029) & (K Units)

Table 88. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2018-2023) & (USD Million)

Table 89. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2024-2029) & (USD Million)

Table 90. Live Attenuated Herpes Zoster Vaccine Raw Material

Table 91. Key Manufacturers of Live Attenuated Herpes Zoster Vaccine Raw Materials

Table 92. Live Attenuated Herpes Zoster Vaccine Typical Distributors

Table 93. Live Attenuated Herpes Zoster Vaccine Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Live Attenuated Herpes Zoster Vaccine Picture
- Figure 2. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Suitable Age, (USD Million), 2018 & 2022 & 2029
- Figure 3. Global Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Suitable Age in 2022
- Figure 4. 40-50 Years Old Examples
- Figure 5. 50-60 Years Old Examples
- Figure 6. 60-70 Years Old Examples
- Figure 7. >70 Years Old Examples
- Figure 8. Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Figure 9. Global Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Application in 2022
- Figure 10. Hospital Examples
- Figure 11. Clinic Examples
- Figure 12. Epidemic Prevention Center Examples
- Figure 13. Others Examples
- Figure 14. Global Live Attenuated Herpes Zoster Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
- Figure 15. Global Live Attenuated Herpes Zoster Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
- Figure 16. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity (2018-2029) & (K Units)
- Figure 17. Global Live Attenuated Herpes Zoster Vaccine Average Price (2018-2029) & (US\$/Unit)
- Figure 18. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Manufacturer in 2022
- Figure 19. Global Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Manufacturer in 2022
- Figure 20. Producer Shipments of Live Attenuated Herpes Zoster Vaccine by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021
- Figure 21. Top 3 Live Attenuated Herpes Zoster Vaccine Manufacturer (Consumption Value) Market Share in 2022
- Figure 22. Top 6 Live Attenuated Herpes Zoster Vaccine Manufacturer (Consumption Value) Market Share in 2022

- Figure 23. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Region (2018-2029)
- Figure 24. Global Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Region (2018-2029)
- Figure 25. North America Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029) & (USD Million)
- Figure 26. Europe Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029) & (USD Million)
- Figure 27. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029) & (USD Million)
- Figure 28. South America Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029) & (USD Million)
- Figure 29. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Consumption Value (2018-2029) & (USD Million)
- Figure 30. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Suitable Age (2018-2029)
- Figure 31. Global Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Suitable Age (2018-2029)
- Figure 32. Global Live Attenuated Herpes Zoster Vaccine Average Price by Suitable Age (2018-2029) & (US\$/Unit)
- Figure 33. Global Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Application (2018-2029)
- Figure 34. Global Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Application (2018-2029)
- Figure 35. Global Live Attenuated Herpes Zoster Vaccine Average Price by Application (2018-2029) & (US\$/Unit)
- Figure 36. North America Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Suitable Age (2018-2029)
- Figure 37. North America Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Application (2018-2029)
- Figure 38. North America Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Country (2018-2029)
- Figure 39. North America Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Country (2018-2029)
- Figure 40. United States Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 41. Canada Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 42. Mexico Live Attenuated Herpes Zoster Vaccine Consumption Value and

Growth Rate (2018-2029) & (USD Million)

Figure 43. Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Suitable Age (2018-2029)

Figure 44. Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Application (2018-2029)

Figure 45. Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Country (2018-2029)

Figure 46. Europe Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Country (2018-2029)

Figure 47. Germany Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 48. France Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 49. United Kingdom Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 50. Russia Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 51. Italy Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 52. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Suitable Age (2018-2029)

Figure 53. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Application (2018-2029)

Figure 54. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Region (2018-2029)

Figure 55. Asia-Pacific Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Region (2018-2029)

Figure 56. China Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 57. Japan Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. Korea Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 59. India Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 60. Southeast Asia Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 61. Australia Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 62. South America Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Suitable Age (2018-2029)

Figure 63. South America Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Application (2018-2029)

Figure 64. South America Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Country (2018-2029)

Figure 65. South America Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Country (2018-2029)

Figure 66. Brazil Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 67. Argentina Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 68. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Suitable Age (2018-2029)

Figure 69. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Application (2018-2029)

Figure 70. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity Market Share by Region (2018-2029)

Figure 71. Middle East & Africa Live Attenuated Herpes Zoster Vaccine Consumption Value Market Share by Region (2018-2029)

Figure 72. Turkey Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 73. Egypt Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 74. Saudi Arabia Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 75. South Africa Live Attenuated Herpes Zoster Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 76. Live Attenuated Herpes Zoster Vaccine Market Drivers

Figure 77. Live Attenuated Herpes Zoster Vaccine Market Restraints

Figure 78. Live Attenuated Herpes Zoster Vaccine Market Trends

Figure 79. Porters Five Forces Analysis

Figure 80. Manufacturing Cost Structure Analysis of Live Attenuated Herpes Zoster Vaccine in 2022

Figure 81. Manufacturing Process Analysis of Live Attenuated Herpes Zoster Vaccine

Figure 82. Live Attenuated Herpes Zoster Vaccine Industrial Chain

Figure 83. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 84. Direct Channel Pros & Cons

Figure 85. Indirect Channel Pros & Cons

Figure 86. Methodology

Figure 87. Research Process and Data Source

I would like to order

Product name: Global Live Attenuated Herpes Zoster Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G8043DEE67BCEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8043DEE67BCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

